Compare AETR & LITS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AETR | LITS |
|---|---|---|
| Founded | 1995 | 2000 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 36.1M | 36.3M |
| IPO Year | 2006 | 2003 |
| Metric | AETR | LITS |
|---|---|---|
| Price | $1.54 | $0.81 |
| Analyst Decision | Buy | |
| Analyst Count | 3 | 0 |
| Target Price | ★ $4.25 | N/A |
| AVG Volume (30 Days) | 35.1K | ★ 257.2K |
| Earning Date | 11-12-2026 | 11-10-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 13.81 |
| EPS | N/A | ★ 0.48 |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $8.74 | N/A |
| P/E Ratio | ★ N/A | $1.75 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $1.58 | $0.69 |
| 52 Week High | $2.05 | $1.99 |
| Indicator | AETR | LITS |
|---|---|---|
| Relative Strength Index (RSI) | 12.63 | 36.17 |
| Support Level | N/A | $0.69 |
| Resistance Level | $1.75 | $1.24 |
| Average True Range (ATR) | 0.09 | 0.09 |
| MACD | -0.03 | -0.01 |
| Stochastic Oscillator | 4.65 | 22.59 |
Lite Strategy Inc is focused on the clinical development of novel therapies for cancer. The company's portfolio of drug candidates includes voruciclib, an oral cyclin-dependent kinase 9 (CDK9) inhibitor, and zandelisib, an oral, once-daily, selective PI3K inhibitor. It is a clinical-stage pharmaceutical company committed to the development of novel and differentiated cancer therapies intended to improve outcomes for patients. The company operates in the segments: Digital Asset Treasury Strategy and Development of Pharmaceutical Products.